Since CD4+ T cells from MS patients show reduced levels of TGF-β signaling components [124], the initial failure of a clinical trial using TGF-β2 for MS [125] could be due to the lowered responsiveness of TGF-βs in the pathologies of MS. This evidence concerns the gene TGFB2 and myeloid sarcoma.